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Cochlea sparingAbstract Introduction: Radiotherapy of the posterior fossa is routinely delivered using 3DCRT
parallel-opposed lateral ﬁelds. However high incidence of sensorineural hearing loss, hypotha-
lamic–pituitary dysfunction, thyroid and gonadal dysfunction during radiotherapy makes the need
for treatment plan which provides adequate coverage of the target volume while sparing of the
cochlea and other surrounding organs at risk (OARs) at same time inevitable.
Aim of the work: To compare the coverage of posterior fossa and the dose to surrounding OARs
including non-posterior fossa brain, pituitary, cochlea, eyes, optic nerves, optic chiasm, cervical
spinal cord, thyroid gland, pharynx, parotid glands and mandible using three different 3DCRT
plans.
Methods: Ten patients underwent CT simulation for treatment planning of posterior fossa boost.
The CT data were transferred to Precise Elekta treatment planning system where posterior fossa,
non-posterior fossa brain, pituitary, cochlea, parotid glands, cervical spinal cord, thyroid gland,
pharynx, mandible, eyes, lenses, optic nerves and optic chiasm were all contoured.
For each patient, three plans were carried out; two parallel opposed open lateral photon ﬁelds, a
pair of wedged posterior oblique ﬁelds, and a pair of wedged posterior oblique ﬁelds and an open
vertex ﬁeld.
312 A. Helal et al.For all plans, the dose distributions and dose volume histogram parameters (DVPs) for the PTV
and OARs were compared and analyzed statistically using excel sheet 2003 and SPSS spreadsheet
(SPSS base 18).
Results: Posterior fossa dose coverage and its homogeneity were adequate and comparable for the
three plans. A part from high mean dose received by cochlea, plan 1 shows the best sparing for other
OARs.
Conclusion: 3DCRT using parallel opposed ﬁelds is recommended for posterior fossa irradiation
boost as it minimizes the exit dose to all structures other than the cochlea, however its mean dose
was within the tolerance.
ª 2013 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Primary central nervous system (CNS) tumors are the most
common solid tumors in children. The posterior fossa is the
site of about half of these tumors, including medulloblastomas,
cerebellar and brainstem astrocytomas, and fourth ventricular
ependymomas.1 In Egypt medulloblastoma is a common
tumor, and constitutes about 19% of primary intracranial
neoplasms.2
Most children with brain tumors (including medulloblas-
toma) will require radiotherapy during the course of their
management. Radiotherapy of posterior fossa tumors is tech-
nically challenging, and radiation-induced side effects have
been a primary concern in those patients. The concern has
been the greatest for patients with average-risk medulloblas-
toma, for whom long-term disease control is expected, and
the side effects of therapy have more signiﬁcant lasting
impact.3
Radiotherapy of the posterior fossa is routinely delivered
using 3DCRT parallel-opposed lateral ﬁelds. However it is
technically challenging because of radiation-induced side
effects for surrounding OARs. Although the exit doses may
be in the surrounding normal brain and other critical struc-
tures; the entrance dose from a vertex ﬁeld may also contribute
to additional dose to the normal supra tentorium.3
Although ﬁve-year free and overall survival rates were 81
and 86% respectively in one of the COG trials, ototoxicity
was reported in approximately 25% of the patients in this
trial.4,5
Ototoxicity is the most important adverse effect of treat-
ment as radiation beams cover the inner ear. It impairs the
child’s cognitive function and quality of life.6 Although the
tolerance of the cochlea to radiation is not known, the inci-
dence of Ototoxicity was low for a cochlear mean dose of
30 Gy or less and increased at doses greater than 40–
45 Gy.7 Ototoxicity has been found to be more signiﬁcant
when radiotherapy and cisplatin chemotherapy are used in
combination.8,9 Hearing loss occurred after doses greater
than 50–60 Gy.10
There has been some concern in the pediatric radiation
oncology community regarding this method of delivering the
posterior fossa boost. In two-dimensional radiotherapy,
opposed lateral ﬁelds are used to treat the posterior fossa com-
partment; exit doses of each ﬁeld are conﬁned mainly to the
posterior fossa. The high incidence of sensorineural hearing
loss during radiotherapy treatment planning of post fossa
makes the need for treatment plan which provides adequatecoverage of the target volume while sparing the cochlea at
same time inevitable.1
2. Aim of the work
This study aimed to compare the coverage of posterior fossa
and the dose to surrounding OARs including non-posterior
fossa brain, pituitary, cochlea, eyes, optic nerves, optic chiasm,
cervical spinal cord, thyroid gland, pharynx, parotid glands
and mandible for three different 3DCRT plans in a way to cre-
ate an optimum plan that shows adequate target coverage and
sparing of these OARs.3. Methods
Ten children diagnosed as having medulloblastoma included in
the present study were referred to Alexandria Clinical Oncol-
ogy Department (ACOD), Alexandria Faculty of Medicine
from January 2011 to March 2012 for craniospinal irradiation
and post fossa irradiation boost. A computed tomography
(CT) simulation was performed at a slice thickness of 3 mm
from the top of the head to the mid-pelvis. Patients were
immobilized using individual thermoplastic head masks with
shoulder ﬁxation which extended to the base of the skull to
ensure reproducible positioning.
The CT data were transferred to Precise Elekta treatment
planning system. After all patients had received craniospinal
irradiation (CSI) with two lateral parallel opposed ﬁelds to
the head and a matched posterior spine ﬁeld, all required struc-
tures necessary for posterior fossa irradiation were contoured.
They include posterior fossa and OARs. The PTV was con-
structed by adding a margin of 7 mm around the posterior
fossa. OARs including non-posterior fossa brain, pituitary,
cochlea, parotid glands, cervical spinal cord, thyroid gland,
pharynx, mandible, eyes, lenses, optic nerves and optic chiasm
were all contoured.
For each patient three plans were created using 6 MV pho-
ton beams; (a) two parallel opposed lateral open ﬁelds, (b) a
pair of posterior oblique wedged ﬁelds, and (c) a pair of pos-
terior oblique wedged ﬁelds and an open vertex ﬁeld (Fig. 1).
The gantry and collimator angles of obliques and vertex beams
were adjusted to spare most of OARs. Wedge angles used were
15, 25 and 30. Couch angle was 90 for vertex. The ﬁeld size
was deﬁned by the beam’s eye view of the PTV and
MLCs were used to shape the beams and to spare close by
OARs. The dose prescribed was 18 Gy to posterior fossa in
Figure 1 Field arrangements for the three techniques used in irradiating the posterior fossa: (A) parallel-opposed lateral ﬁelds; (B) two
posterior oblique wedged ﬁelds; (C) two posterior oblique wedged ﬁelds with a vertex ﬁeld. It also shows post fossa in red, both parotids in
green, cochlea and pharynx in blue, spinal cord in violet.
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treatment of 36 Gy).
For all plans, isodose distributions and DVHs were gener-
ated. Plan evaluation and comparison depend on dose cover-
age of PTV, its conformity and homogeneity and the sparing
of OARs. The coverage of PTV was evaluated using D95%
and maximum dose. Dose homogeneity index within PTV
was calculated for all patients by dividing the maximum dose
of the PTV by its minimum. The DVPs which determine the
tolerance and so the sparing of OARs were also compared.
4. Statistical analysis
For all patients, DVPs were recorded. The differences and %
of reduction of the DVPs of PTV and different OARs between
the plans were calculated and analyzed statistically using excel
sheet 2003 and SPSS Wilcoxon signed Rank test (version 18).
5. Results
By reviewing the DVPs of the three treatment plans for all
patients, the followings are the results as regards the dose dis-
tribution of the PTV and OARs including non-posterior fossa
brain, pituitary, cochlea, parotid glands, cervical spinal cord,
thyroid gland, pharynx, mandible, eyes, lenses, optic nerves
and optic chiasma (Table 1 and Fig. 2): Table 1 gives the sta-
tistical analysis and DVPs for PTV and OARs comparing the
three plans.
5.1. PTV dosimetry
PTV coverage (D95%) is adequate and comparable for plans 1
and 2 and it is signiﬁcantly better for plan 3. PTV max. dose is
comparable for plans 1 and 2 and it is signiﬁcantly lower for
plan 3 compared to plan 1. Although the dose is more homo-
geneous for plan 3 compared to plans 1 and 2, theses differ-
ences are not signiﬁcant. Body max dose is accepted and
comparable for the three plans.
5.2. OAR dosimetry
Using two parallel opposed lateral open ﬁelds (plan 1) shows
the least mean doses for parotids, pharynx and mandible fol-
lowed by plan 3 and then plan 2. Plan 1 also shows the leastmean dose for pituitary and eyes and the least max. point dose
to the spinal cord, optic chiasm, optic nerves and lenses fol-
lowed by plan 2 and then plan 3.
Although Plan 2 shows the least mean dose for both
cochlea followed by plan 3 then plan 1, Plan 1 & 2 show the
least mean dose for non posterior fossa brain followed by plan
3. On the other hand, plan 3 shows the least mean dose for thy-
roid followed by plan 1 & 2. Table 1 shows the percentage of
reduction in DVPs of different OARs between the three plans
and whether these reductions are signiﬁcant or not.
Although the three plans show adequate dose coverage and
homogeneity within PTV, using two parallel opposed lateral
open ﬁelds (plan 1) shows some advantages; the least mean
dose for parotids, pharynx and mandible, pituitary, non post
fossa brain and eyes and the least max. point dose to the spinal
cord, optic chiasm, optic nerves and lenses. On the other hand
it shows non signiﬁcant greatest dose to both cochlea as they
are entirely present within the parallel opposed ﬁelds. How-
ever, the advantage of using a pair of posterior oblique wedged
ﬁelds (plan 2) and a pair of posterior oblique wedged ﬁelds
with vertex ﬁeld (plan 3) is sparing of the cochlea.6. Discussion
3DCRT for post. fossa boost allows delivery of the prescribed
dose to posterior fossa while minimizing the dose to surround-
ing OARs. This is important in children with medulloblastoma
which is a common childhood malignancy with various critical
structures such as the developing brain, bone, thyroid gland,
pituitary gland, and cochlea may not be fully developed.3 Also,
as the majority of patients will survive (long-term survival in
this disease is about 55–65%).11 Recent reports highlighted
the importance of minimizing the dose to these OARs below
their tolerance values during cranio spinal and/or posterior
fossa boost irradiation, otherwise, late effects of radiation ther-
apy such as somatic and carcinogenic effects may be observed
during the follow-up period.3,11
The current study compared three techniques for irradia-
tion of post. fossa; two parallel opposed open lateral photon
ﬁelds, a pair of wedged posterior oblique ﬁelds, and a pair of
wedged posterior oblique ﬁelds with an open vertex ﬁeld. In
the current study, although the average of the mean dose
received by both cochlea was greater for plans 2 and 3
(98%, 89% and 90%) respectively compared with the ﬁgures
Table 1 Comparison of the average of DVPs of PTV and OARs irradiated by three different techniques for post fossa patients (all are
in %). P values for the differences between the plans are also shown.
DVPs Plan 1 Plan 2 Plan 3 Diﬀerences % plan
1/ 2 P values
Diﬀerences % plan
1/ 3 P values
Diﬀerences % plan
2/ 3 P values
PTV D95% 98.5 98 99 0.5 0.5 1
0.892 0.041 0.026
PTVmax 110 110 108 0 1.8 1.8
0.952 0.014 0.098
Homogeneity index 1.27 1.27 1.24 0 2 2
0.959 0.444 0.059
Rt. Parotid mean 20 30.5 28 34 28.5 8
0.005 0.005 0.005
Lt. Parotid mean 19 28 26 32 27 7
0.065 0.074 0.073
Rt.C mean 98 85 87 13 11 2
0.139 0.153 0.007
Lt. C. mean 98 93 93 5 5 0
0.138 0.202 0.165
Pharynx mean 3 6 6 50 50 0
0.004 0.005 0.683
Thyroid mean 0.6 0.6 0.5 0 17 17
1 0.317 0.317
Mandible mean 2.5 4.5 4 44 37.5 11
0.010 0.008 0.317
Pituitary mean 35.5 48 57 26 38 16
0.011 0.005 0.005
Spinal cord max 38 47 48 19 21 2
0.047 0.059 0.645
Non P.F.brainmean 21 21 30 0 30 30
0.234 0.005 0.005
Optic chiasm max 29 39 51 26 43 23.5
0.018 0.005 0.005
Rt. optic nerve max 6 8 21 25 71 62
0.096 0.005 0.008
Lt. optic nerve max 12 12 24 0 50 50
0.340 0.017 0.007
Rt. Eye mean 1 1 3 0 67 67
0.083 0.039 0.109
Lt. Eye mean 2 3 4.5 33 55 33
0.071 0.011 0.033
Rt lens max. 0.7 0.9 3 22 77 70
0.414 0.008 0.011
Lt lens max. 1.4 1.7 2 17 30 15
0.414 0.034 0.180
Body max dose 108 108 107 0 0.9 0.9
0.535 0.581 0.280
314 A. Helal et al.achieved by Paulino et al.3 (100%, 50% and 42%) respectively,
on the other hand, the average in the current study was still
within tolerance (52 Gy = 16 Gy + 36 Gy; 16 Gy delivered
by post fossa boost (90% X 18 Gy) added to 36 Gy from cra-
niospinal irradiation).
In the current study the average of the mean dose to non-
posterior fossa brain using plans 1 and 2 was comparable
and lower than plan 3 which showed the highest average of
the mean dose among the three plans (21%, 21% and 30%)
respectively. Although these ﬁgures were comparable to those
achieved by Paulino et al.3 (22%, 22% and 39%) respectively,
on the other hand, the mean dose of plan 3 in the current study
was lower than what they achieved. In contrast to Paulino
et al.3 results, the average of the mean dose to the pituitarygland using plans 2 and 3 was far higher in the current study
(35.5%, 48% and 57%) respectively compared to in their study
(36%, 19% and 21%) respectively.
The average of the mean dose to the mandible was the least
for plan 1 followed by plan 3 and then plan 2 (2.5%, 4.5% and
4%) respectively this is in accordance to Paulino et al.3 results
(8%, 14% and 11%),but our ﬁgures were far lower.
The average of the mean dose to thyroid was lower in the
current study (0.6%, 0.6%, and 0.5%) respectively compared
to Paulino et al.3 study (0%, 1% and 3%) respectively.
The average of the mean dose to both parotids was lower in
plan 1 followed by plan 3 then plan 2 (19%, 29% and 27%)
respectively this agrees with Paulino et al.3 (13%, 34% and
25%) respectively.
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B  
C  
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A  
B  
C  
Non post. fossa brain
A  
B  
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C  A  
B  
Cochlea 
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A
Figure 2 Dose volume histograms for OARs. (A) parallel-opposed lateral ﬁelds; (B) two posterior oblique wedged ﬁelds; (C) two
posterior oblique wedged ﬁelds with a vertex ﬁeld. All are in %.
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showed the average of the mean dose to the pharynx was far
lower for the three plans (3%, 6% and 6%) respectively com-
pared to the ﬁgures in their study (8%, 13% and 12%).
So the results of the current work agree with Paulino et al.3
in; plan 1 shows the lowest mean dose to mandible, parotids
and pharynx, plans 1 and 2 show the lowest mean dose to
non post fossa brain, and plans 2 and 3 achieve the lowest
mean dose to cochlea. For both studies thyroid dose was very
low for all plans. On the other hand the results are different in;
the lowest dose to pituitary was in plan 1 in the current study
and in plan 2 in their work.In both studies; the main advantage of using posterior obl-
iques and post obliques with vertex is minimizing the dose to
both cochlea while the main disadvantage is higher dose to
parotid glands, mandible and pharynx, and to non post fossa
brain when a vertex ﬁeld is used.
Fukunaga-Johnson et al.12 compared the dose received by
both cochlea, pituitary and mandible using plans 1 and 2.
The cochlear dose for each patient was calculated as an aver-
age between the right and the left cochlea due to symmetry
of the problem so the dose distributions between the right
and left cochlea were essentially equivalent. For plans 1 and
2, the average of the mean dose of both cochlea was (100%
316 A. Helal et al.and 70%) respectively of the prescribed dose compared to
(98% and 89%) respectively in the current work. The average
of the mean dose to the pituitary was far higher in their work
(48% and 68%) respectively compared to (35.5% and 48%)
respectively in the current work. On the other hand, the aver-
age of mean dose of the mandible was far lower in their work
(0.8% and 1.8%) respectively compared to (2.5% and 4.5%)
respectively in the current work.
So for both studies; plan 1 shows the highest dose to cochlea,
and the lowest dose to pituitary andmandible compared to plan
2. Moreover in the current study our ﬁgures for pituitary only
were far lower than those achieved in their study.
In Breen et al.1 study using opposing and oblique ﬁelds, the
average of the mean dose to the cochlea delivered by both
plans respectively was lower (97–100% and 65–84%) respec-
tively compared to (98% and 89%) respectively in our work.
For none post fossa brain; the average of the mean dose was
far higher (46–61% and 36–51%) respectively compared to
(21% and 21%) in our work. For optic nerves; the max point
dose was lower (2–2.8% and 4–13%) respectively compared to
(6% and 12%) respectively in our work. For lenses; max. Point
dose was higher (0.9–1.4% and 1.8–2.3%) respectively com-
pared to (0.7–0.9% and 1.4–1.7%) respectively in our work.
For pituitary; the average of the mean dose was higher (15–
38% and 56–60%) respectively compared to (35.5% and
48%) respectively in our work. For the spinal cord; the max
point dose was higher (14–77% and 14–78%) respectively
compared to (38% and 47%) respectively in our work). They
attributed their results to; the use of posterior oblique ﬁelds
can exclude the cochlea from the ﬁelds, thereby reducing their
dose, however, as the exit dose will be in structures anterior
and close by to the posterior fossa so their doses are increased
compared to opposed lateral ﬁelds. Comparing both studies,
except for the mean dose of cochlea and max. point dose of
optic nerve which were higher in the current study, our ﬁgures
are far lower than those achieved in their study.
3DCRT open opposed lateral ﬁelds showed the lowest dose
to all critical structure except both cochlea which received the
target dose because of their proximity to the target volume.
However as the average of the mean dose to cochlea
(53.6Gy) was still within tolerance (17.6Gy delivered by poster-
ior fossa boost (98% X 18Gy) added to 36Gy from craniospi-
nal irradiation) so we recommend to use it for posterior fossa
boost irradiation.7. Conclusion
3DCRT using parallel opposed ﬁelds is recommended for pos-
terior fossa irradiation boost as it minimizes the exit dose to all
structures other than the cochlea, however its mean dose was
within the tolerance.Conﬂict of interest
None declared.
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